USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: LIPELLA PHARMACEUTICALS, INC.
Address: 5414 GUARINO RD
PITTSBURGH, PA
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $199,617.00 2
SBIR Phase II $1,749,282.00 2
STTR Phase I $740,688.00 1

Award List:

Intravesical Liposome Treatment for Interstitial Cystitis

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: Jonathan H. Kaufman
Award Amount: $99,617.00
Abstract:
DESCRIPTION (provided by applicant): Interstitial cystitis (IC) is a chronic, severely debilitating disease of the urinary bladder. It can be described as a chronic inflammatory condition of the bladder wall, characterized by urinary frequency and urgency, and severe suprapubic and/or pelvic pain.… More

Intravesical Liposome Treatment for Interstitial Cystitis

Award Year / Program / Phase: 2008 / SBIR / Phase II
Agency: HHS
Principal Investigator:
Award Amount: $750,000.00
Abstract:
DESCRIPTION (provided by applicant): Interstitial cystitis (IC) is a chronic, severely debilitating disease of the urinary bladder. It can be described as a chronic inflammatory condition of the bladder wall, characterized by urinary frequency and urgency, and severe suprapubic and/or pelvic pain.… More

Bladder drug delivery using intravesical liposomes to treat overactive bladder

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Jonathan H. Kaufman
Award Amount: $100,000.00
Abstract:
DESCRIPTION (provided by applicant): Lipella Pharmaceutical Inc has been successful with development of intravesical liposome for painful bladder syndrome/Interstitial cystitis (PBS/IC). Through SBIR funding, Lipella has been successful in establishing the pre-clinical safety of its primary… More

Developing Intravesical Liposomes for Interstitial Cystitis

Award Year / Program / Phase: 2009 / STTR / Phase I
Agency: HHS
Research Institution: WILLIAM BEAUMONT HOSPITAL
Principal Investigator: Jonathan H. Kaufman
Award Amount: $740,688.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): LP08 is a novel intravesical treatment for interstitial cystitis (IC), a poorly understood chronic disorder of unknown etiology consisting of irritative bladder symptoms and pelvic pain that dramatically affects quality of life. In IC/PBS, two distinct subtypes… More

Bladder drug delivery using intravesical liposomes to treat overactive bladder

Award Year / Program / Phase: 2011 / SBIR / Phase II
Agency: HHS
Principal Investigator: Jonathan H. Kaufman – 412-901-0315
Award Amount: $999,282.00
Abstract:
DESCRIPTION (provided by applicant): Lipella Pharmaceuticals Inc. has been funded by National Institutes of Health Small Business Innovation and Research (SBIR) grants to develop intravesical liposome nanoparticles to treat overactive bladder (OAB), interstitial cystitis/painful bladder syndrome… More